Nanochon Abstract Presented at AAOS 2026
Charlotte K Barton1, Kathryn Seabaugh 1, Ben Gadomski 2, Kevin Labus 2, Ben Holmes 3, Nathan Castro 3, Mike Hawes […]
Charlotte K Barton1, Kathryn Seabaugh 1, Ben Gadomski 2, Kevin Labus 2, Ben Holmes 3, Nathan Castro 3, Mike Hawes […]
Capital Nanochon has closed another oversubscribed round, bringing in new capital and increasing the total amount raised to $4.1M. This
This article was originally published on UVA Today This Alum’s Tech May Revolutionize Knee Joint Replacements Benjamin Holmes can pinpoint
WASHINGTON, January 12, 2026 — Nanochon, a Washington, DC-based orthopedic device company developing an implant for treating articular cartilage defects
Emilia Aram , David C. Flanigan, MD, Nathan J. Castro, PhD, Doug Snell, Luke Aram Purpose: Osteochondral defects can present
Charlotte K Barton BVSc, MS, DACVS-LA, MS, MS, Katie A Seabaugh DVM, MS, DACVS-LA, DACVSMR, Ben Gadomski BS, PhD, Kevin
Nanochon has secured commitments to close oversubscribed convertible note, bringing our total capital raised to date to $11.3 million. While the majority of this bridge was filled by current investors, we’re thrilled to welcome a few new folks onto our cap table.
The Maryland Stem Cell Research Commission, the body overseeing The Maryland Stem Cell Research Fund (MSCRF), has awarded Nanochon grant
Washington, DC, July 14 2025 – Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant
Under the direction of CEO Benjamin Holmes, Nanochon, Inc. is set to revolutionize the treatment of cartilage loss and damage.